The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Reduced m6A modification predicts malignant phenotypes and augmented Wnt/PI3K‐Akt signaling in gastric cancer
Open accessAbstract
Background: As the most abundant epigenetic modification on mRNAs and long non‐coding RNAs, N6‐methyladenosine (m6A) modification extensively exists in mammalian cells. Controlled by writers (methyltransferases), readers (signal transducers), and erasers (demethylases), m6A influences mRNA structure, maturation, and stability, thus negatively regulating protein expression in a post‐translational manner. Nevertheless, current understanding of m6A's roles in tumorigenesis, especially in gastric cancer (GC) remains to be unveiled. In this study, we assessed m6A's clinicopathological relevance to GC and explored the underlying mechanisms. Methods: By referring to a proteomics‐based GC cohort we previously generated and the TCGA‐GC cohort, we merged expressions of canonical m6A writers (METTL3/METTL14), readers (YTHDF1/YTHDF2/YTHDF3), and erasers (ALKBH5/FTO), respectively, as W, R, and E signatures to represent m6A modification. We stratified patients according to these signatures to decipher m6A's associations with crucial mutations, prognosis, and clinical indexes. m6A's biological functions in GC were predicted by gene set enrichment analysis (GSEA) and validated by in vitro experiments. Results: We discovered that W and R were potential tumor suppressive signatures, while E was a potential oncogenic signature in GC. According to W/R/E stratifications, patients with low m6A‐indications were accompanied with higher mutations of specific genes (CDH1, AR, GLI3, SETBP1, RHOA, MUC6, and TP53) and also demonstrated adverse clinical outcomes. GSEA suggested that reduced m6A was correlated with oncogenic signaling and phenotypes. Through in vitro experiments, we proved that m6A suppression (represented by METTL14 knockdown) promoted GC cell proliferation and invasiveness through activating Wnt and PI3K‐Akt signaling, while m6A elevation (represented by FTO knockdown) reversed these phenotypical and molecular changes. m6A may also be involved in interferon signaling and immune responses of GC. Conclusions: Our work demonstrated that low‐m6A signatures predicted adverse clinicopathological features of GC, while the reduction of RNA m6A methylation activated oncogenic Wnt/PI3K‐Akt signaling and promoted malignant phenotypes of GC cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Comprehensive molecular characterization of gastric adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13480 · Cited by 6,498
Topology of the human and mouse m6A RNA methylomes revealed by m6A-seq
Dominissini, D., Moshitch-Moshkovitz, S., Schwartz, S., Salmon-Divon, M., Ungar, L., Osenberg, S., Cesarkas, K., Jacob-Hirsch, J., Amariglio, N., Kupiec, M., et al. (2012) · Nature · doi:10.1038/nature11112 · Cited by 4,884
N6-methyladenosine-dependent regulation of messenger RNA stability
Wang, X., Lu, Z., Gomez, A., Hon, G. C., Yue, Y., Han, D., Fu, Y., Parisien, M., Dai, Q., Jia, G., et al. (2014) · Nature · doi:10.1038/nature12730 · Cited by 4,558
ALKBH5 Is a Mammalian RNA Demethylase that Impacts RNA Metabolism and Mouse Fertility
Zheng, G., Dahl, J. A., Niu, Y., Fedorcsak, P., Huang, C.-M., Li, C. J., Vågbø, C. B., Shi, Y., Wang, W.-L., Song, S.-H., et al. (2013) · Molecular Cell · doi:10.1016/j.molcel.2012.10.015 · Cited by 3,550
A METTL3–METTL14 complex mediates mammalian nuclear RNA N6-adenosine methylation
Liu, J., Yue, Y., Han, D., Wang, X., Fu, Y., Zhang, L., Jia, G., Yu, M., Lu, Z., Deng, X., et al. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1432 · Cited by 3,433
Coudray, N., Ocampo, P. S., Sakellaropoulos, T., Narula, N., Snuderl, M., Fenyö, D., Moreira, A. L., Razavian, N., & Tsirigos, A. (2018) · Nature Medicine · doi:10.1038/s41591-018-0177-5 · Cited by 2,930
Zhan, T., Rindtorff, N., & Boutros, M. (2017) · Oncogene · doi:10.1038/onc.2016.304 · Cited by 2,626
N6-methyladenosine-dependent RNA structural switches regulate RNA–protein interactions
Liu, N., Dai, Q., Zheng, G., He, C., Parisien, M., & Pan, T. (2015) · Nature · doi:10.1038/nature14234 · Cited by 1,988
PI3K and cancer: lessons, challenges and opportunities
Fruman, D. A., & Rommel, C. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4204 · Cited by 1,709
The many faces and functions of β‐catenin
Valenta, T., Hausmann, G., & Basler, K. (2012) · The EMBO Journal · doi:10.1038/emboj.2012.150 · Cited by 1,598
m 6 A mRNA methylation facilitates resolution of naïve pluripotency toward differentiation
Geula, S., Moshitch-Moshkovitz, S., Dominissini, D., Mansour, A. A., Kol, N., Salmon-Divon, M., Hershkovitz, V., Peer, E., Mor, N., Manor, Y. S., et al. (2015) · Science · doi:10.1126/science.1261417 · Cited by 1,533
The Obesity-Associated FTO Gene Encodes a 2-Oxoglutarate-Dependent Nucleic Acid Demethylase
Gerken, T., Girard, C. A., Tung, Y.-C. L., Webby, C. J., Saudek, V., Hewitson, K. S., Yeo, G. S. H., McDonough, M. A., Cunliffe, S., McNeill, L. A., et al. (2007) · Science · doi:10.1126/science.1151710 · Cited by 1,527
FTO Plays an Oncogenic Role in Acute Myeloid Leukemia as a N 6 -Methyladenosine RNA Demethylase
Li, Z., Weng, H., Su, R., Weng, X., Zuo, Z., Li, C., Huang, H., Nachtergaele, S., Dong, L., Hu, C., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2016.11.017 · Cited by 1,508
Zhang, S., Zhao, B. S., Zhou, A., Lin, K., Zheng, S., Lu, Z., Chen, Y., Sulman, E. P., Xie, K., Bögler, O., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.02.013 · Cited by 1,459
Chen, M., Wei, L., Law, C., Tsang, F. H., Shen, J., Cheng, C. L., Tsang, L., Ho, D. W., Chiu, D. K., Lee, J. M., et al. (2018) · Hepatology · doi:10.1002/hep.29683 · Cited by 1,376
N6-methyladenosine modification destabilizes developmental regulators in embryonic stem cells
Wang, Y., Li, Y., Toth, J. I., Petroski, M. D., Zhang, Z., & Zhao, J. C. (2014) · Nature Cell Biology · doi:10.1038/ncb2902 · Cited by 1,290
m6A RNA Methylation Regulates the Self-Renewal and Tumorigenesis of Glioblastoma Stem Cells
Cui, Q., Shi, H., Ye, P., Li, L., Qu, Q., Sun, G., Sun, G., Lu, Z., Huang, Y., Yang, C.-G., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.02.059 · Cited by 1,252
Vu, L. P., Pickering, B. F., Cheng, Y., Zaccara, S., Nguyen, D., Minuesa, G., Chou, T., Chow, A., Saletore, Y., MacKay, M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4416 · Cited by 1,237
m6A RNA Modification Controls Cell Fate Transition in Mammalian Embryonic Stem Cells
Batista, P. J., Molinie, B., Wang, J., Qu, K., Zhang, J., Li, L., Bouley, D. M., Lujan, E., Haddad, B., Daneshvar, K., et al. (2014) · Cell Stem Cell · doi:10.1016/j.stem.2014.09.019 · Cited by 1,203
Zhao, X., Yang, Y., Sun, B.-F., Shi, Y., Yang, X., Xiao, W., Hao, Y.-J., Ping, X.-L., Chen, Y.-S., Wang, W.-J., et al. (2014) · Cell Research · doi:10.1038/cr.2014.151 · Cited by 1,187
Rethinking m6A Readers, Writers, and Erasers
Meyer, K. D., & Jaffrey, S. R. (2017) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-100616-060758 · Cited by 1,150
Promoter-bound METTL3 maintains myeloid leukaemia by m6A-dependent translation control
Barbieri, I., Tzelepis, K., Pandolfini, L., Shi, J., Millán-Zambrano, G., Robson, S. C., Aspris, D., Migliori, V., Bannister, A. J., Han, N., et al. (2017) · Nature · doi:10.1038/nature24678 · Cited by 1,086
Wang, K., Yuen, S. T., Xu, J., Lee, S. P., Yan, H. H. N., Shi, S. T., Siu, H. C., Deng, S., Chu, K. M., Law, S., et al. (2014) · Nature Genetics · doi:10.1038/ng.2983 · Cited by 1,045
Zhang, C., Samanta, D., Lu, H., Bullen, J. W., Zhang, H., Chen, I., He, X., & Semenza, G. L. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1602883113 · Cited by 971
Self-citationInactivation of the Fto gene protects from obesity
Fischer, J., Koch, L., Emmerling, C., Vierkotten, J., Peters, T., Brüning, J. C., & Rüther, U. (2009) · Nature · doi:10.1038/nature07848 · Cited by 949
RNA N6-methyladenosine methylation in post-transcriptional gene expression regulation
Yue, Y., Liu, J., & He, C. (2015) · Genes & Development · doi:10.1101/gad.262766.115 · Cited by 922
Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer
Quigley, D. A., Dang, H. X., Zhao, S. G., Lloyd, P., Aggarwal, R., Alumkal, J. J., Foye, A., Kothari, V., Perry, M. D., Bailey, A. M., et al. (2018) · Cell · doi:10.1016/j.cell.2018.06.039 · Cited by 733
Reading m6A in the Transcriptome: m6A-Binding Proteins
Patil, D. P., Pickering, B. F., & Jaffrey, S. R. (2018) · Trends in Cell Biology · doi:10.1016/j.tcb.2017.10.001 · Cited by 628
Schwartz, S., Agarwala, S. D., Mumbach, M. R., Jovanovic, M., Mertins, P., Shishkin, A., Tabach, Y., Mikkelsen, T. S., Satija, R., Ruvkun, G., et al. (2013) · Cell · doi:10.1016/j.cell.2013.10.047 · Cited by 626
Alspach, E., Lussier, D. M., & Schreiber, R. D. (2019) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a028480 · Cited by 603
The Two Faces of Interferon-γ in Cancer
Zaidi, M. R., & Merlino, G. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0482 · Cited by 593
m6A modulates haematopoietic stem and progenitor cell specification
Zhang, C., Chen, Y., Sun, B., Wang, L., Yang, Y., Ma, D., Lv, J., Heng, J., Ding, Y., Xue, Y., et al. (2017) · Nature · doi:10.1038/nature23883 · Cited by 582
Self-citationImmune checkpoints and their inhibition in cancer and infectious diseases
Dyck, L., & Mills, K. H. G. (2017) · European Journal of Immunology · doi:10.1002/eji.201646875 · Cited by 541
m6A modification controls the innate immune response to infection by targeting type I interferons
Winkler, R., Gillis, E., Lasman, L., Safra, M., Geula, S., Soyris, C., Nachshon, A., Tai-Schmiedel, J., Friedman, N., Le-Trilling, V. T. K., et al. (2019) · Nature Immunology · doi:10.1038/s41590-018-0275-z · Cited by 455
Gastric cancer—molecular and clinical dimensions
Wadhwa, R., Song, S., Lee, J.-S., Yao, Y., Wei, Q., & Ajani, J. A. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.170 · Cited by 423
E-cadherin: Its dysregulation in carcinogenesis and clinical implications
Wong, S. H. M., Fang, C. M., Chuah, L.-H., Leong, C. O., & Ngai, S. C. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.11.010 · Cited by 400
IGF2BP1 promotes SRF-dependent transcription in cancer in a m6A- and miRNA-dependent manner
Müller, S., Glaß, M., Singh, A. K., Haase, J., Bley, N., Fuchs, T., Lederer, M., Dahl, A., Huang, H., Chen, J., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky1012 · Cited by 379
Pan-Cancer Landscape of Aberrant DNA Methylation across Human Tumors
Saghafinia, S., Mina, M., Riggi, N., Hanahan, D., & Ciriello, G. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.09.082 · Cited by 357
Expression of E- and P-cadherin in gastric carcinomas.
Shimoyama, Y., & Hirohashi, S. (1991) · PubMed · Cited by 342
Cross-talk among writers, readers, and erasers of m 6 A regulates cancer growth and progression
Panneerdoss, S., Eedunuri, V. K., Yadav, P., Timilsina, S., Rajamanickam, S., Viswanadhapalli, S., Abdelfattah, N., Onyeagucha, B. C., Cui, X., Lai, Z., et al. (2018) · Science Advances · doi:10.1126/sciadv.aar8263 · Cited by 339
Mimura, K., Teh, J. L., Okayama, H., Shiraishi, K., Kua, L., Koh, V., Smoot, D. T., Ashktorab, H., Oike, T., Suzuki, Y., et al. (2018) · Cancer Science · doi:10.1111/cas.13424 · Cited by 329
Nass, S. J., Herman, J. G., Gabrielson, E. W., Iversen, P. W., Parl, F. F., Davidson, N. E., & Graff, J. R. (2000) · PubMed · Cited by 292
A proteomic landscape of diffuse-type gastric cancer
Ge, S., Xia, X., Ding, C., Zhen, B., Zhou, Q., Feng, J., Yuan, J., Chen, R., Li, Y., Ge, Z., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03121-2 · Cited by 288
Self-citationCombination Cancer Therapies with Immune Checkpoint Blockade: Convergence on Interferon Signaling
Minn, A. J., & Wherry, E. J. (2016) · Cell · doi:10.1016/j.cell.2016.03.031 · Cited by 271
Zhang, C., Zhi, W. I., Lu, H., Samanta, D., Chen, I., Gabrielson, E., & Semenza, G. L. (2016) · Oncotarget · doi:10.18632/oncotarget.11743 · Cited by 259
Self-citationRNA m6 A modification enzymes shape innate responses to DNA by regulating interferon β
Rubio, R. M., Depledge, D. P., Bianco, C., Thompson, L., & Mohr, I. (2018) · Genes & Development · doi:10.1101/gad.319475.118 · Cited by 236
Genetic alterations of m6A regulators predict poorer survival in acute myeloid leukemia
Kwok, C.-T., Marshall, A. D., Rasko, J. E. J., & Wong, J. J. L. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0410-6 · Cited by 199
Lau, M.-T., So, W., & Leung, P. C. K. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059083 · Cited by 116
Kanai, Y., Ushijima, S., Tsuda, H., Sakamoto, M., & Hirohashi, S. (2000) · Cancer Letters · doi:10.1016/s0304-3835(99)00316-x · Cited by 108
Epigenomic map of human liver reveals principles of zonated morphogenic and metabolic control
Brosch, M., Kattler, K., Herrmann, A., von Schönfels, W., Nordström, K., Seehofer, D., Damm, G., Becker, T., Zeissig, S., Nehring, S., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06611-5 · Cited by 98
Immune checkpoints and immunotherapy for colorectal cancer
Singh, P. P., Sharma, P. K., Krishnan, G., & Lockhart, A. C. (2015) · Gastroenterology report · doi:10.1093/gastro/gov053 · Cited by 96
Huang, T.-S., Li, L., Moalim-Nour, L., Jia, D., Bai, J., Yao, Z., Bennett, S. A. L., Figeys, D., & Wang, L. (2014) · Stem Cells · doi:10.1002/stem.1944 · Cited by 80
Osaki, L. H., Bockerstett, K. A., Wong, C. F., Ford, E. L., Madison, B., DiPaolo, R. J., & Mills, J. C. (2018) · The Journal of Pathology · doi:10.1002/path.5214 · Cited by 79
Gastric Cancer Genomics: Advances and Future Directions
Katona, B. W., & Rustgi, A. K. (2017) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2017.01.003 · Cited by 78
Zhang, S., Tang, Q., Xu, F., Xue, Y., Zhen, Z., Deng, Y., Liu, M., Chen, J., Liu, S., Qiu, M., et al. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0248 · Cited by 74
Mucins and Wnt/β-catenin signaling in gastrointestinal cancers: an unholy nexus
Pai, P., Rachagani, S., Dhawan, P., & Batra, S. K. (2016) · Carcinogenesis · doi:10.1093/carcin/bgw005 · Cited by 64
Senescence markers: Predictive for response to checkpoint inhibitors
Moreira, A., Groß, S., Kirchberger, M. C., Erdmann, M., Schuler, G., & Heinzerling, L. (2018) · International Journal of Cancer · doi:10.1002/ijc.31763 · Cited by 62
Predicting the Functional Impact of CDH1 Missense Mutations in Hereditary Diffuse Gastric Cancer
Melo, S., Figueiredo, J., Fernandes, M. S., Gonçalves, M. S., Morais‐de‐Sá, E., Sanches, J., & Seruca, R. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18122687 · Cited by 56
Gastric cancer and Hedgehog signaling pathway: emerging new paradigms
Akyala, A. I., & Peppelenbosch, M. P. (2018) · Genes & Cancer · doi:10.18632/genesandcancer.168 · Cited by 53
Song, H., Yu, Z., Sun, X., Feng, J. L., Qi, Y., Khan, H., Zhu, X., Huang, L., Li, M., Mok, M. T. S., et al. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.08.043 · Cited by 53
Zheng, H., Takahashi, H., Nakajima, T., Murai, Y., Cui, Z., Nomoto, K., Tsuneyama, K., & Takano, Y. (2006) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-006-0135-3 · Cited by 52
Korshunov, A., Sahm, F., Zheludkova, O., Голанов, А. В., Stichel, D., Schrimpf, D., Ryzhova, M. V., Aa, P., Habel, A., Meyer, J., et al. (2018) · Neuro-Oncology · doi:10.1093/neuonc/noy155 · Cited by 48
Adiponectin inhibits hepatic stellate cell activation by targeting the PTEN/AKT pathway
Kumar, P., Raeman, R., Chopyk, D. M., Smith, T., Verma, K., Liu, Y., & Anania, F. A. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.08.012 · Cited by 37
Kwon, J.-A., Lee, S.-Y., Ahn, E.-K., Seol, S., Kim, M. C., Kim, S. J., Kim, S. I., Chu, I., & Leem, S. (2010) · Human Mutation · doi:10.1002/humu.21289 · Cited by 34
Timmermans‐Sprang, E. P. M., Gracanin, A., & Mol, J. A. (2015) · BMC Cancer · doi:10.1186/s12885-015-1544-y · Cited by 27
Zhu, L., Yan, F., Wang, Z., Dong, H., Bian, C.-L., Wang, T., Yu, E., & Li, J. (2018) · International Journal of Cancer · doi:10.1002/ijc.31765 · Cited by 26
A new player SETs in myeloid malignancy
Trimarchi, T., Ntziachristos, P., & Aifantis, I. (2013) · Nature Genetics · doi:10.1038/ng.2709 · Cited by 15
Cited by
m6A Modification in Coding and Non-coding RNAs: Roles and Therapeutic Implications in Cancer
Huang, H., Weng, H., & Chen, J. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.02.004 · Cited by 1,226
The potential role of RNA N6-methyladenosine in Cancer progression
Wang, T., Kong, S., Tao, M., & Ju, S. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01204-7 · Cited by 1,013
The role of m6A RNA methylation in cancer metabolism
An, Y., & Duan, H. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01500-4 · Cited by 871
Tang, B., Yang, Y., Kang, M., Wang, Y., Wang, Y., Bi, Y., He, S., & Shimamoto, F. (2020) · Molecular Cancer · doi:10.1186/s12943-019-1128-6 · Cited by 327
RetractedMechanism of RNA modification N6-methyladenosine in human cancer
Zhou, Z., Lv, J., Yu, H., Han, J., Yang, X., Feng, D., Wu, Q., Yuan, B., Lu, Q., & Yang, H. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01216-3 · Cited by 275
Metadata
- Authors
- Zhang, C., Zhang, M., Ge, S., Huang, W., Lin, X., Gao, J., Gong, J., & Shen, L.
- Venue
- Cancer Medicine
- Publisher
- Wiley
- Published
- 2019-06-26
- Volume
- 8
- Issue
- 10
- Pages
- 4766-4781
- ISSN
- 2045-7634 (ISSN-L)
- OpenAlex
- W2955121251
- Cited by
- 283
- References
- 68
- FWCI
- 12.96
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.